Clinical Scorecard: Impact of Genetic Ancestry on the Efficacy and Toxicity of Idecabtagene Vicleucel in Patients with Relapsed/Refractory Multiple Myeloma

At a Glance

Key Highlights

• Genetic ancestry groups (African, European, Admixed American) show distinct baseline disease and demographic characteristics in RRMM patients treated with ide-cel.
• No significant differences in overall response rate, progression-free survival, or overall survival by genetic ancestry despite baseline disparities.
• Higher African ancestry associated with increased aggressive disease features, worse performance status, and numerically higher rates of neurotoxicity (ICANS).

Guideline-Based Recommendations

Diagnosis

• Use International Myeloma Working Group criteria for response assessment.
• Incorporate genetic ancestry estimation via germline DNA genotyping to better characterize patient populations.

Management

• Administer idecabtagene vicleucel as per clinical trial protocols or standard of care for RRMM.
• Monitor for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) post-infusion.

Monitoring & Follow-up

• Assess for hematologic toxicities and organ involvement pre- and post-CAR-T therapy.
• Follow patients longitudinally for at least 18 months to evaluate efficacy and safety outcomes.

Risks

• Patients with higher African ancestry may have increased risk of severe cytopenias and neurotoxicity.
• Baseline inflammatory markers and comorbidity burden may influence toxicity profiles.

Patient & Prescribing Data

Heavily pretreated RRMM patients with diverse genetic ancestry (African, European, Admixed American).

Despite baseline differences, ide-cel demonstrates comparable efficacy across genetic ancestry groups; toxicity profiles may vary, necessitating tailored monitoring.

Clinical Best Practices

• Incorporate genetic ancestry analysis to complement self-identified race/ethnicity for personalized risk assessment.
• Closely monitor patients with high African ancestry for CRS and ICANS given observed trends toward increased neurotoxicity.
• Consider baseline disease aggressiveness and performance status when planning CAR-T therapy and supportive care.
• Maintain awareness of medication burden and comorbidities that may impact treatment tolerance.

References

• International Myeloma Working Group criteria
• KarMMa-3 trial subgroup analysis
• 1000 Genomes Project reference populations